Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Mohamad Kadri

Adolescent Medicine Los Angeles, CA Medical Doctor

NPI 1538192166 CMS profile 520993

1155N Vermont Ave Ste 2013, Alkadry Corp, Los Angeles, CA 90029

Open in the dashboard

General payments

$5,020

102 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohamad Kadri of Los Angeles, CA is reported in the CMS Open Payments database as having received $5,020 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $857 27
2024 General $1,906 39
2023 General $2,195 33
2022 General $62 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohamad Kadri
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Mohamad Kadri were reported at $857. Among 40 Adolescent Medicine profiles paid that year, the median was $135 and the middle half received between $78 and $573.

Show as a table
Year Mohamad Kadri Adolescent Medicine median Middle half National median
2019 $0 $112 $24–$444 $163
2020 $0 $80 $35–$250 $114
2021 $0 $229 $55–$448 $132
2022 $62 $162 $35–$492 $149
2023 $2,195 $182 $54–$507 $160
2024 $1,906 $142 $59–$362 $164
2025 $857 $135 $78–$573 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Regeneron Healthcare Solutions, Inc. $685 17 payments
  2. Amgen Inc. $500 4 payments
  3. Genzyme Corporation $487 9 payments
  4. Cranial Technologies, Inc $423 25 payments
  5. AstraZeneca Pharmaceuticals LP $339 3 payments
  6. Merck Sharp & Dohme Corporation $302 11 payments
  7. Lilly USA, LLC $209 2 payments
  8. GlaxoSmithKline, LLC. $191 4 payments
  9. Dexcom, Inc. $132 3 payments
  10. Horizon Therapeutics plc $131 1 payment
  11. Other $1,622 23 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,002 101 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19 1 payment
Products named General payments · program years 2022–2025
  1. DUPIXENT Immunology $754 11 payments
  2. DUPIXENT Inflammation And Immunology $439 11 payments
  3. Doc Band $423 25 payments
  4. Otezla $369 3 payments
  5. ZENPEP $249 2 payments
  6. DUPIXENT Immunology And Inflammation $246 6 payments
  7. XYOSTED $240 3 payments
  8. MOUNJARO $209 2 payments
  9. VAXNEUVANCE $201 10 payments
  10. GARDASIL 9 $181 9 payments
  11. Other $3,051 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record